Gossamer Bio 2025 Q2 Earnings Sharp Net Income Decline of 177.7%

Gossamer Bio (GOSS) reported its Q2 2025 earnings on August 5, 2025, delivering results that significantly missed expectations due to a substantial net loss. The company swung from a profit to a loss, with a 177.7% deterioration in net income. It did not adjust guidance, maintaining its focus on advancing its clinical and commercial strategies.

Revenue
The company’s total revenue plummeted by 88.0% year-over-year to $11.49 million in Q2 2025, driven entirely by revenue from contracts with collaborators, which accounted for the full $11.49 million in total revenue.

Earnings/Net Income
Gossamer Bio swung to a net loss of $38.27 million in Q2 2025, a 177.7% decline from a net income of $49.23 million in the same period the prior year. On a per-share basis, the company reported a loss of $0.17, down from a profit of $0.22 per share in 2024 Q2, representing a 177.3% negative change. Despite the loss, the company noted a new record high for Q2 net income in the past year, indicating mixed performance.

Price Action
The GOSS stock price edged down 0.69% in the latest trading day but surged 74.19% month-to-date, reflecting strong volatility and investor interest following the earnings release.

Post Earnings Price Action Review
A strategy of buying Gossamer Bio shares after its quarterly revenue report and holding for 30 days has historically underperformed, returning -92.97% over the past three years. This approach has also shown a maximum drawdown of 0.00% and a Sharpe ratio of -0.60, indicating a high-risk profile and poor returns relative to the benchmark, underperforming by 141.55%.

CEO Commentary
Faheem Hasnain, CEO, emphasized the company’s strategic transition from a clinical-stage biotech to a commercial organization in partnership with Chiesi Group, underscoring progress in commercial planning for seralutinib. He expressed confidence in the upcoming pivotal readout in PAH and outlined plans for the SERANATA Study in PH-ILD, with first site activations expected in Q4 2025. The CEO highlighted disciplined execution and the potential of seralutinib to become a multi-billion-dollar franchise.

Guidance
The company expects to report topline results from the PROSERA Phase 3 Study in February 2026 and anticipates activating the first sites for the SERANATA Phase 3 Study in Q4 2025. It currently holds $212.9 million in cash, cash equivalents, and marketable securities, which is projected to fund operations through 2027.

Additional News
On August 6, 2025, Gossamer Bio announced its Q2 2025 financial results, reiterating its focus on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). The SERANATA Study, which will enroll approximately 480 patients randomized 1:1:1 to receive 90mg, 120mg, or placebo, will evaluate the 6MWD at week 24 as its primary endpoint. The company remains positioned to advance its pipeline while strengthening its commercial infrastructure in partnership with Chiesi Group.